Crispr Therapeutics Ag
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-09-20 | Thomas R. Suozzi · D-NY | House | Sold | $50,001 - $100,000 |
| 2021-01-21 | Marjorie Taylor Greene · R-GA | House | Bought | $1,001 - $15,000 |
| 2018-06-19 | James M. Inhofe · R-OK | Senate | Sold | $15,001 - $50,000 |
| 2017-10-19 | James M. Inhofe · R-OK | Senate | Bought | $15,001 - $50,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.